Oral fluoropyrimidines in colorectal cancer.
Van Cutsem
E
E
Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
Peeters
M
M
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; C073482:eniluracil; D014498:Uracil; D010094:Oxonic Acid; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil